Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, May 19 2017

Full Issue

Blood Tests May Have 'Significantly' Underestimated Lead Levels, FDA Warns

The tests the agency are warning about, though, are not used as often as less invasive screenings, so it should not affect most people, according to officials. However, pregnant women and children should be retested, they say.

The Washington Post: Blood Tests Significantly Underestimated Lead Levels, FDA And CDC Warn

Federal officials are warning that some blood tests may have “significantly” underestimated lead levels, and they are urging the retesting of some children, as well as pregnant and breast-feeding women. The Food and Drug Administration and the Centers for Disease Control and Prevention said the tests in question were made by Magellan Diagnostics, a Massachusetts-based testing company whose products are used in laboratories and doctors' offices throughout the country. The problem may go as far back as 2014, the agency said. The warning applies only to tests in which blood samples are taken from a vein, not the more common, less invasive tests in which fingers or heels are pricked for a blood sample. (McGinley, 5/17)

The New York Times: F.D.A. Warns Of Faulty Lead Testing In Children And Mothers

The concern is that the original tests may have underestimated blood lead levels, providing false assurance to parents. Infants and young children are especially vulnerable to the effects of lead poisoning, which can cause cognitive deficits and affect almost every system in the body. (Rabin, 5/17)

The Wall Street Journal: FDA Warns On Magellan Diagnostics Lead Blood Tests

Dr. Patrick Breysse of the CDC estimated that fewer than 1% of lead tests performed on residents of Flint, Mich., were of the venous variety in question. In that city the water system was tainted with lead in a widely publicized case that led to criminal charges against city and state officials and an $87 million payout from the state to replace lead pipes. (Burton, 5/17)

NPR: Common Lead Test Can Give False Results, FDA Warns

The majority of lead tests are not conducted with that kind of blood sample, but rather blood from a heel or finger prick, says Dr. Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health. "We have no evidence that Magellan's tests, when used with blood obtained from a finger or heel stick, are impacted," says Shuren. "We believe most people will not be affected by this issue." (Greenfieldboyce, 5/17)

The Baltimore Sun: Some Lead Tests Inaccurate, Health Officials Say

Meridian Bioscience, of which Magellan is a subsidiary, said the companies "take these matters very seriously and will continue to work closely and fully with the FDA and CDC to address the concerns identified with venous samples as quickly as possible." (McDaniels, 5/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF